McGill.CA / Cancer Prevention / Publications / Dr. Pollak's publications

Dr. Pollak's publications 2008-2009

2008

  1. Rajpathak SN, McGinn AP, Strickler HD, Rohan TE, Pollak M, Cappola AR, Kuller L, Xue X, Newman AB, Strotmeyer ES, Psaty BM, Kaplan RC. Insulin-like growth factor-axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res 18: 166-73, 2008.
  2. Borugian MJ, Spinelli JJ, Sun Z, Kolonel LN, Oakley-Girvan I, Pollak M, Whittemore AS, Wu AH, Gallagher RP. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a prospective multiethnic study. Cancer Epidemiol Biomarkers Prev 17: 252-4, 2008.
  3. Okereke OI, Pollak MN, Hu FB, Hankinson SE, Selkoe DJ, Grodstein F. Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes. Psychoneuroendocrinology 33: 455-61, 2008.
  4. Kaplan RC, McGinn AP, Pollak MN,, Kuller L, Strickler HD, Rohan TE, Xue X, Kritchevsky SB, Newman AB, Psaty BM. Total insulin like growth factor 1 and insulin like growth factor binding protein levels, functional status, and mortality in older adults. J Am Geriatr Soc 56: 652-60, 2008.
  5. Kasper JS, Liu Y, Pollak MN, Rifai N, Giovannucci E. Hormonal profile of diabetic men and the potential link to prostate cancer. Cancer Causes Control 19: 703-10, 2008.
  6. Ades S, Koushik A, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F, Roger M, Franco EL; Biomarkers of Cervical Cancer Risk (BCCR) Study Team (Michael Pollak is member). Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. Int J Cancer 122: 2820-6, 2008.
  7. Diorio C, Brisson J, Berube S, Pollak M. Genetic polymorphisms involved in insulin-like growth factor (IGF-I) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Biomarkers Prev 17: 880-8, 2008.
  8. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X, Ho GY, Einstein MH, Kaplan RC, Burk RD, Wylie-Rosett J, Pollak MN, Anderson G, Howard BV, Strickler HD. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarker Prev 17: 921-9, 2008.
  9. van Oijen M, Okereke OI, Kang JH, Pollak MN, Hu FB, Hankinson SE, Grodstein F. Fasting insulin levels and cognitive decline in older women without diabetes. Neuroepidemiology 30: 174-9, 2008.
  10. Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a high energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 15: 833-9, 2008.
  11. Diorio C, Brisson J, Berube S, Pollak M. Intact and total insulin-like growth factor-binding protein-3 levels in relation to breast cancer risk factors: a cross-sectional study. Br Cancer Res 10: R42, 2008.
  12. Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Sharma A, Enriquez Sarano M, Pollak M, Jagannath S, Richardson P, Gualberto A. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulin like growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 26: 3196-203, 2008.
  13. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 110: 246-50, 2008.
  14. Kaplan RC, McGinn AP, Pollak MN, Kuller L, Strickler HD, Rohan TE, Cappola AR, Xue X, Psaty BM. High insulin like growth factor binding protein 1 level predicts incident congestive heart failure in the elderly. Am Heart J 155: 1006-12, 2008.
  15. Max JB, Limburg PJ, Ogunseitan A, Stolzenberg-Solomon RZ, Vierkant RA, Pollak M, Sellers TA, Virtamo J, Cerhan JR, Albanes D. IGF-I, IGFBP-3, and IGF-I/IGFBP-3 Ratio: No Association with Incident Colorectal Cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Cancer Epidemiol Biomarkers Prev 17: 1832-4, 2008.
  16. Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, Penson DF, Thompson IM, Kristal AR. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate 68: 1477-86, 2008.
  17. Okereke OI, Selkoe DJ, Pollak MN, Stampfer MJ, Hu FB, Hankinson SE, Grodstein F. A profile of impaired insulin degradation in relation to late-life cognitive decline: A preliminary investigation. Int J Geriatr Psychiatry 2008 Jul 8.
  18. Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Cox DG, Dorronsoro M, Dossu L, Haiman CA, Hankinson SE, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Linseisen J, Lund E, Manjer J, McCarty C, Peeters PH, Pike MC, Pollak M, Riboli E, Stram DO, Tjonneland A, Travis RC, Trichopoulos D, Tumino R, Yeager M, Ziegler RG, Feigelson HS; Breast and Prostate Cancer Cohort Consortium. IGF-1, IGFBP-1, IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS ONE 3: e2578, 2008.
  19. Page JH, Ma J, Pollak M, Manson JE, Hankinson SE. Plasma insulin-like growth factor 1 and binding-protein 3 and risk of myocardial infarction in women: a prospective study. Clin Chem 54: 1682-8, 2008.
  20. Pollak M. Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol 8: 384-92, 2008.
  21. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen P, Gaziano JM, Pollak M, Stampfer M. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9: 1039-47, 2008.
  22. Zakikhani M, Dowling RJO, Sonenberg N, Pollak MN. Effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res 1: 369-75, 2008.
  23. Diorio C, Sinotte M, Brisson J, Berube S, Pollak M. Vitamin d pathway polymorphisms in relation to mammographic breast density. Cancer epidemiol Biomarkers Prev 17: 2505-8, 2008.
  24. Fuchs CS, Goldberg RM, Sargen DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M. Plasma insulin-like growth factors, insulin-like binding protein-3 and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res 14: 8263-9, 2008.
  25. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 2008.[In Press]
  26. Stolzenberg-Solomon RZ, Weinstein S, Pollak M, Tao Y, Taylor PR, Virtamo J, Albanes D. Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. 168: 1047-55, 2008.
  27. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schröder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP Jr, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149: 461-71,W83-8, 2008.
  28. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14: 6364-70, 2008.
  29. Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 10: R86, 2008.
  30. Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Cancer Rev 8: 915-28, 2008.
  31. So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MCU, Nielsen TO, Gleave M, Pollak M. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 14: 6944-54, 2008.
  32. Pollak M. Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22: 625-38, 2008.
  33. Sinotte M, Diorio C, Berube S, Pollak M, Brisson J. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr. 2008 Dec 30. Epub ahead of print.
  34. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68: 10238-46, 2008.

TOP OF PAGE

2009

  1. Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, Pollak M. Insulin receptor expression by human prostate cancers. The Prostate 69: 33-40, 2009.
  2. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27: 176-85, 2009.
  3. Sinotte M, Diorio C, Berube S, Pollak M, Brisson J. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr 89: 634-40, 2009.
  4. Pollak M. Energy metabolism, cancer risk, and cancer prevention. Recent Results Cancer Res 181: 51-4, 2009.
  5. Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, Zakikhani M, Carboni JM, Gottardis M, Giunti A, Pollak M, Vigneri R, Baldini N. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res 69: 2443-52, 2009.
  6. Pollak, M. Aging, IGF-1, and diet. Aging Cell. 2009 Mar 5.
  7. Kaplan RC, Fitzpatrick AL, Pollak MN, Gardner JP, Jenny NS, McGinn AP, Kuller LH, Strickler HD, Kimura M, Psaty BM, Aviv A. Insulin-Like Growth Factors and Leukocyte Telomere Length: The Cardiovascular Health Study J Gerontol A Biol Sci Med Sci 2009 Apr 6.
  8. Pollak, M. Do cancer cells care if their host is hungry? Cell Metab 2009.
  9. Rohrmann S, Sutcliffe CG, Bienstock JL, Monsegue D, Akereyeni F, Bradwin G, Rifai N, Pollak MN, Agurs-Collins T, Platz EA.Racial variation in sex steroid hormones and the insulin-like growth factor axis in umbilical cord blood male neonates. Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1484-91.
  10. Mavropoulos JC, Buschemeyer WC 3rd, Tewari AK, Fokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, PIzzo SV, Freedland SJ. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prev Res (Phila Pa) 2: 557-65, 2009.
  11. Dowling RJ, Pollak M, Sonenberg N. Current status and challenges associated with targeting mTOR for cancer therapy. BioDrugs 23: 77-91, 2009.
  12. Su X, Colditz GA, Willett WC, Collins LC, Schnitt SJ, Connolly JL, Pollak MN, Rosner B, Tamimi RM. Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. Int J Cancer 126: 180-90, 2009.
  13. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28: 3009-21, 2009.
  14. Pollak M. Macronutrient intake and cancer: how does dietary restriction influence tumor growth and why should we care? Cancer Prev Res (Phila Pa) 2: 698-701, 2009.
  15. Beauchamp MC, Knafo A, Yasmeen A, Carboni JM, Gottardis MM, Pollak MN, Gotlieb WH. BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. Gynecol Oncol 115: 193-8, 2009.
  16. Gualberto A, Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets 10: 923-36, 2009.
  17. Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, Lipton A, Demers L, Leitzel K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualberto A. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor Figitumumab (CP-751,871) in combination with Paclitaxel and Carboplatin. J Thorac Oncol 4: 1397-403, 2009.
  18. Barbieri M, Paolisso G, Kimura M, Gardner JP, Boccardi V, Papa M, Hjelmborg JV, Christensen K, Brimacombe M, Nawrot TS, Staessen JA, Pollak MN, Aviv A. Higher circulating levels of igf-1 are associated with longer leukocyte telomere length in healthy subjects. Mech Ageing Dev 130: 771-6, 2009.
  19. Khalid S, Hwang D, Babichev Y, Kolli R, Altamentova S, Koren S, Goodwin PJ, Ennis M, Pollak M, Sonenberg N, Fantus IG. Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. Breast Cancer Res Treat. 2009 Oct 23. Epub ahead of print.
Tags: 
Pollak
publications
Back to top